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ABSTRACT 
The present manuscript describe simple, sensitive, rapid, accurate, precise and economical first derivative spectrophotometric method for the 
simultaneous determination of Irbesartan(IRB) and Atorvastatin  (ATR) in synthetic mixture. The derivative spectrophotometric method was based 
on the determination of both the drugs at their respective zero crossing point (ZCP). The first order derivative spectra was obtained in methanol 
and the determinations were made at 225.20 nm (ZCP of IAtorvastatin) for Irbesartan  and 308.15 nm (ZCP of Irbesartan) for Atorvastatin. The 
linearity was obtained in the concentration range of succinate 5-30 μg/ml for Irbesartan and 5- 30 μg/ml for Atorvastatin Succinate. The mean 
recovery was 99.25 and 99.65% for Irbesartan and Atorvastatin succinate, respectively. The method was found to be simple, sensitive, accurate and 
precise and was applicable for the simultaneous determination of Irbesartan and Atorvastatin in synthetic mixture. The results of analysis have 
been validated statistically and by recovery studies.The proposed method is recommended for routine analysis since they are rapid,simple, accurate 
and also sensitive and specific by no heating and no organic solvent extraction. 
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INTRODUCTION 
 Irbesartan, an angiotensin II receptor antagonist [1].Is used mainly 
for the treatment of hypertension. It is an orally active nonpeptide 
tetrazole derivative and selectively inhibits angiotensin II receptor 
type 2. Angiotensin II receptor type1 antagonists have been widely 
used in treatment of diseases like hypertension, heart failure, 




Fig.1  Structure of Irbesartan[3] 
Irbesartan is white or almost white, crystalline powder. Solubility is 
given in practically insoluble in water, sparingly soluble in methanol, 
slightly soluble in methylene chloride. 
Atorvastatin is used as lipid-lowering agents used in 
hyperlipidaemia condition.Atorvastatin selectively and 
competitively inhibits the hepatic enzyme HMG-CoA reductase.[4]As 
HMG-CoA reductase is responsible for converting HMG-CoA to 
mevalonate in the cholesterol biosynthesis pathway, this results in a 
subsequent decrease in hepatic cholesterol levels and decreases 
blood cholesterol level. 
Fig. 2: Structureofatorvastatin[5] 
Atorvastatin 
iswhiteoralmostwhite,crystallinepowder.Solubilityisgiveninpractical
ly insoluble in water, soluble in methanol, slightlysolublein 
methylenechloride. 
Hypertension frequently coexists with hyperlipidaemia and both are 
considered to be major risk factors for developing cardiac disease 
ultimately resulting in adverse cardiac events. This clustering of risk 
factors is potentially due to a common mechanism. Further, patient 
compliance with the management of hypertension is generally better 
than patient compliance with hyperlipidaemia. It would therefore be 
advantageous for patients to have a single therapy which treats both 
of these conditions with help of fixed dose combination of Irbesartan 
and atorvastatin.[6,7] 
The review of literature regarding quantitative analysis of 
Irbesartan and atorvastatinrevealed that no attempt was made to 
develop analytical methods for Irbesartan and atorvastatin. Some 
spectrometric methods and chromatographic methods have been 
reported for theestimation of the individual drugs.The focus of the 
present study was to develop and validate a rapid, stable, specific, 
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and economic spectroscopic method for the estimation of Irbesartan 
and atorvastatinin Synthetic mixture.[8,9] 
MATERIALS AND METHODOLOGY 
 Atorvastatin and Irbesartan were obtained as gift samples from 
S Kant pharmaceuticals and CTX life science Surat. Synthetic 
Mixture contain 20mg of Atorvastatin and 160mg of Irbesartan. 
 A double beam UV/Visible spectrophotometer (Shimadzu 
model 2450, Japan) with spectral width of 2 nm, 1 cm quartz 
cells was used to measure absorbance of all the solutions.  
 Spectra were automatically obtained by UV-Probe system 
software. 
 An analytical balance (Sartorius CD2250, Gottingen, Germany) 
was used for weighing the samples.  
 Sonicator(D120/2H, TRANS-O-SONIC) 
 Class ‘A’ volumetric glassware were used (Borosillicte) 
Standard solutionofIrbesartan  (IRB) 
Preparation of stock solution of IRB 
Accurately weighed quantity of Irbesartan 10 mg was transferred to 
100 ml volumetric flask, dissolved and diluted up to mark with 
methanol to give a stock solution having strength of 100μg/ml. 
Preparation of stock solution of ATR 
Accurately weighed quantity of Atorvastatin 10mg was transferred 
to 100 ml volumetric flask, dissolved and diluted up to mark with 
methanol to give a stock solution having strength of 100μg/ml. 
Preparation of standard mixture solution 
From the stock solution of IRB take 3.2ml and from stock solution of 
ATR take 0.4ml and transferred in to 10ml volumetric flask and 
diluted up to mark with methanol to give a solution having strength 
of IRB was 32 μg/ml and ATR was 4 μg/ml. 
Preparation of test solution 
From the stock solution of IRB take 3.2ml and from stock solution of 
ATR take 0.4ml and transferred in to 10ml volumetric flask and 
diluted up to mark with methanol to give a solution having strength 
of IRB was 32 μg/ml and ATR was 4 μg/ml. 
Calibration curves for Irbesartan   
Pipette out 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 ml of the stock solution of 
Irbesartan and atorvastatin  (100μg/ml) into a series of 10ml 
volumetric flasks and the volume was adjusted to mark with 
methanol and measured absorbance at 225.20nm and 308.15nm. 
Plotte the graph of absorbance versus respective concentration of 
Irbesartan and atorvastatin. Linearity 
range of IRB and ATR was found with correlation co-efficient. 
First Order Derivative Spectrophotometric Method 
Development of Method 
Different solutions were prepared in the different solvents according 
to the solubility of the drugs. It was found that methanol showing 
good overlay and distinct λmax of the both drugs. Therefore, it can be 
easy to measure the response of the both drugs in the combined 
mixture. The λmax of the Irbesartan  and Atorvastatin was found to be 
226.00 nm and 246.00 nm respectively in methanol. 
Thesynthetic mixtureofIrbesartan andAtorvastatinispresentin 
8:1ratios,respectively.Theabsorptionspectraofpuredrug 
andtheirmixturewere recorded between 200-400 nm using  Distilled 
Water as solvent and proceed to first derivativespectra.TheIRB 
wasshowstheZCPat308.15nmandATRshowsthe ZCP at 225.20nm.  
On thebasis theseIRB can bequantified bymeasuringthe 
absorbanceat225.20nmandATRcanbequantifiedbymeasuringtheabs
orbanceat 308.15nm.  
 
Fig.3:  Overlainzero orderspectraofIRB andATR in methanol 
(1:1) 
 
Fig. 4: Overlain firstorderspectra ofIRB andATR in8:1 
ratios,respectivelywith thecombination solution (8:1) 
 




2 2 5 . 2 0 nm  (ZCPofATR)forIRB (1-6µg/ml)and 
3 0 8 . 1 5 nm(ZCPofIRB)forATR(25-
150µg/ml)withcorrelationcoefficient(r2)of0.9996and0.9996forIRB 
and ATR, respectively. 
Thismethodobeyedbeer’slawintheconcentrationrange1-




andATRwasfound to be 0.9996 and 0.9996,respectively(figure6and 
7) 
Theregression line equation forIRB and ATR are as following, 
y = -0.0008x - 0.0003for IRB _____________ (1) 
y = -0.0011x + 0.003 for ATR ______________ (2) 
 
Fig. 5 Overlainlinearfirstorderspectra ofIRB (Pink) 
andATR(Blue) in8:1 ratios 
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FromthecombinationsolutionofIRB andATRthedilutionweremadeinratioof 8:1 andabsorbancewererecorded(Table1)andcorrelationcoefficient(r
2
)of 
0.9938 (figure6) and 0.9984(figure6) for IRB and ATR, respectively. 
 
Table 1:Calibrationdata forIRB andATRat 225.20nmand308.15nm, respectively. *(n=6) 







1 05 05 -0.00265±0.00058 -0.00412±0.00315 
2 10 10 -0.00612±0.00063 -0.00936±0.00339 
3 15 15 -0.01185±0.00095 -0.01358±0.00316 
4 20 20 -0.01735±0.00065 -0.01795±0.00456 
5 25 25 -0.02246±0.00086 -0.02156±0.00490 
6 30 30 -0.02932±0.00092 -0.02574±0.00413 
 
 




ATRis presented in Table 2 
 





Fig.7CalibrationcurveforATR at 308.15nm 
 
 
Table 2 Intraday precision data for estimation ofIRB andATR*(n=3) 
Conc. (μg/ml) Abs. (IRB)* % RSD Abs. (ATR)* % RSD 
Avg. ± SD(225.20nm) Avg.± SD(308.15nm) 
IRB ATR     
5 5 -0.00374 -0.65 -0.00205 -0.68 
15 15 -0.01258 -0.43 -0.01073 -0.5 




ATRis presented in Table 3 
 





Table 3 Interday precision data for estimation ofIRB andATR*(n=3) 
Conc. (μg/ml) Abs.* (IRB) % RSD Abs. (ATR)* % RSD 
Avg. ± SD(225.20nm) Avg.± SD(308.15nm) 
IRB ATR     
5 5 -0.0041 ± 0.00035 0.84 -0.0023 ± 0.00020 0.89 
15 15 -0.0135 ± 0.00010 0.72 -0.0117 ± 0.00051 0.49 




mixture at threelevels (80%, 100%, and 120%) of standard addition. 
The% recoveryvalues aretabulated in Table 4and 5 
PercentagerecoveryforIRB 
andATRbythismethodwasfoundintherange of98.95 to 101.56% 
and99.16 to 100.5%, respectively, 
Thevalueof%RSDwithinthelimitindicatedthatthemethodisaccuratean
d percentagerecoveryshows that thereis no interferencefrom the 
excipients. 
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Table 4: Recovery data ofIRB *(n=3) 
Conc. Amount of Std.IRB 
added  (µg/ml) 
Total amount of 
IRB  (µg/ml) 
Total amount ofIRB 
found (µg/ml) 
% Recovery* (n=3) % RSD IRB 
ofIRB from formulation 
(µg/ml) 
Mean*± SD 
16 12.8 28.8 28.5 ± 0.25 98.95 0.32 
16 16 32 32.5 ± 0.57 101.56 0.46 
16 19.2 35.2 35.3 ± 0.42 100.28 0.33 
 
Table 5Recovery data ofATR*(n=3) 
Conc. Amount of Std.ATR 
added  (µg/ml) 





% Recovery* (n=3) % 
ofATR from 
formulation (µg/ml) 
Mean*± SD RSD ATR 
2 1.6 3.6 3.57 ± 0.078 99.16 0.77 
2 2 4 4.02 ± 0.018 100.5 0.57 
2 2.4 4.4 4.37 ± 0.025 99.31 0.48 
 





TheobtainedLODandLOQresults arepresentedin Table 6 
Table 6LOD andLOQ dataofIRB andATR *(n=10) 
Conc. (μg/ml) Abs.* (IRB) % Abs.* (ATR) % R 
IRB ATR Avg. ± SD(225.20nm) Avg.±SD(308.15nm) 
5 5 -0.0037 ± 0.00082   -0.0023 ± 0.00101   
LOD (μg/ml) 2.396 1.178 
LOQ (μg/ml) 5.29 4.63 
 
Robustness andRuggedness 
Theobtained Ruggedness andRobustness results arepresented in 
table7 




No significant changes in the spectrums were observed, proving that 
the developed method is ruggedand robust. 
 
Table 7RobustnessandRuggedness dataof IRB andATR*(n=3) 
Conc. 
(PPM) 
Irbesartan (Mean Abs.* ±% RSD) 
Instrument 1 Instrument 2 Stock – 1 Stock – 2 
2 -0.0041 ± 0.84 -0.0042 ± 0.94 -0.0042 ± 0.72 -0.0042 ± 0.75 
3 -0.0136 ± 0.73 -0.0145 ± 0.68 -0.0133 ± 0.75 -0.0136 ± 0.73 
4 -0.0255 ± 0.49 -0.0261 ± 0.22 -0.0253± 0.60 -0.0257 ± 0.22 
 Atorvastatin (Mean Abs.* ±% RSD) 
50 -0.0023 ± 0.65 -0.0024 ± 0.61 -0.0023 ± 0.65 -0.0023 ± 0.42 
75 -0.0115 ± 0.49 -0.0119 ± 0.84 -0.0115 ± 0.51 -0.0115 ± 0.86 
100 -0.0296 ± 0.51 -0.0302 ± 0.33 -0.0292 ± 0.34 -0.0294 ± 0.51 
 
APPLICATION OFTHEPROPOSED METHOD FOR ANALYSISOF IRB 
AND ATRIN SYNTHETIC MIXTURE 
Afirstorderderivativespectrumofthesamplesolutioncontaining32µg/
mlof IRB and4µg/mlofATRwasrecordedandtheabsorbanceat 
225.20nmand 308.15nm werenotedforestimation of IRB and ATR, 
respectively.  
TheconcentrationofIRB andATRinmixture wasdeterminedusingthe 
corresponding calibration graph. 
Theresultsfromtheanalysisof synthetic mixturecontaining Irbesartan 
(32mg)and Atorvastatin (4mg) in combination arepresented in 
Table8. 
Thepercentassayshowsthatthereisnointerferencefromexcipientsandt
he proposedmethodcansuccessfully appliedtoanalysisofcommercial 





Table 8 Analysisdata ofcommercial formulation*(n=3) 
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99.25 ± 0.71 
-0.00213  
99.21 ± 0.21 2 -0.0264 -0.00212 
3 -0.0265 -0.00215 
 





Concentration range(µg/ml) 5 – 30 5 - 30 





Accuracy(%Recovery) (n=3) 100.26 99.65 
Intra-dayPrecision (%RSD) (n=3) 0.39-0.65 0.34-0.68 
Inter-dayprecision (%RSD) (n=3) 0.41-0.84 0.38-0.89 
LOD(µg/ml) 3.396 3.178 
LOQ(µg/ml) 10.290 9.630 
Ruggedness and Robustness 0.22-0.94 0.33-0.86 
%Assay 99.25 99.21 
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